PCSK9 is implicated in cardiovascular disease progression through multiple mechanisms, including the degradation of LDL receptors, which elevates circulating LDL levels [55,56]; interaction with Toll-like receptors, leading to inflammatory responses [57]; and binding with the CD36 receptor, promoting blood clotting and platelet activation [58]. Here, PCSK9 is linked to cardiovascular disorder.